Neuroimmunology Program - IDIBAPS

News

  • Fellowship in Clinical Neuroimmunology

    The Neuroimmunology-Multiple Sclerosis Unit of the Hospital Clínic de Barcelona offers a non-paid formative training stage in neuroimmunology, open to young neurologists who have completed their specialty in the last 5 years. The duration of the program will be 1 year (June 2020 to June 2021), and the training activity will be developed both in the clinical field, monographic outpatient consultations (multiple sclerosis, other demyelinating diseases, encephalitis and other antibody-mediated diseases ), neuro-ophthalmology, and pediatric neuroimmunology, such as the laboratory including neuroimaging, and the neuroimmunology laboratory. The interested persons must send a letter of application, complete CV, and 2 letters of recommendation to the attention of the Dr. Albert Saiz, coordinator of the Unit, at the following address: unitatneuroimmuno@clinic.cat

    The selected candidate will have to meet the requirements of the center for Training Halls of Spanish Specialists, and will require the approval of the Teaching Committee of the Hospital Clínic of Barcelona; In the case of foreign specialists, the procedure must be administered approximately 15 months in advance, once once approved by the Teaching Committee, it must be evaluated by the corresponding commission of the Generalitat de Catalunya, and once resolved in a favorable manner, the official authorization of the Ministry of Health, Social Services and Equality must be requested.

  • Neuroimmunology. Call for the postgraduate degree Biology, Biochemistry, Biomedical Engineering or similar

    A selective process is organized for the coverage of one position of a graduate for research support for the CLINICAL FOUNDATION FOR BIOMEDICAL RESEARCH (FCRB) to be part of the research area of ??Clinical and Experimental Neuroimmunology, with temporary contract

  • Invitation to patients with anti-NMDAR encephalitis to participate in a study about the disease

    The study is part of an "Integrated Project of Excellence (PIE)" subsidized by the Carlos III Institute, and is aimed at patients with encephalitis mediated by antibodies against the NMDA receptor (NMDAR) that are in the recovery phase. Anti-NMDAR encephalitis is a serious but potentially curable autoimmune disease that has a slow recovery (between 5 and 36 months). The cause of this slow recovery is unknown, but up to 25% of patients present important and sometimes irreversible cognitive deficits. With the aim of improving knowledge of the disease, improving its treatment, and accelerating clinical recovery, this study tracks patients for a period of two years. During the first year there is an initial visit and three follow-up at 3, 6 and 12 months, and then a final visit at 24 months. Each visit includes a general neurological examination, neuropsychological tests, EEG, functional magnetic resonance that is performed together with memory exercises, and a sleep study for which the patient sleeps one night in the hospital. It facilitates the transport and accommodation of patients and a family member living outside of Barcelona. The study does not include invasive tests except for a blood draw. The inclusion criteria are:

    • Anti-NMDAR encephalitis confirmed, in the recovery phase.
    • Age between 15 and 45 years.
    • Availability to travel to the Hospital Clínic of Barcelona (transport and accommodation facilitated by the study).

    Patients who are in the recovery phase, family members of patients who are in the acute phase of the disease or responsible physicians can contact to obtain more information about the study or schedule a first visit (after the patient is given discharge of the hospitalization) through the following address:

    Hospital Clínic-IDIBAPS

    C / Roselló, 149-153

    08036, Barcelona

    Phone: 932 271 738

    Jdalmau@clinic.cat

    emmartinez@clinic.cat

    descudero@clinic.cat

  • New paper in JAMA Neurology: Assessing Biological and Methodological Aspects of Brain Volume Loss in Multiple Sclerosis

    Brain volume loss is a promising marker of therapeutic response in multiple sclerosis (MS). The MS visual pathway group leaded by E. H. Martinez-Lapiscina recently published in JAMA Neurology a study that aimed to assess the dynamics of this parameter as MS progresses by using different imaging methods.

    We found out that brain volume loss rates were higher in the first 5 years after MS onset with a direct association with steroids and an inverse association with age. To conclude, it seems that proposed brain volume loss threshold of less than 0.4% per year should be reconsidered in future studies. 

  • Presenting an update of the Connectivity Project at the 32nd Plenary Meeting and Workshop of MAGNIMS

    IMAGINEM team presented yesterday an update of the Connectivity project at the 32nd Plenary meeting and Workshop of MAGNIMS, in Amsterdam (Netherlands)

  • XXII Award 2018 Claustre de Doctors de la Universitat de Barcelona

    The Cloister of Doctors of the Universitat de Barcelona, announces the XXII Prize 2018 for the best doctoral thesis presented at the University of Barcelona, during the year 2016. The winner of last year's edition was Dr. Thaís Armangué Salvador, "Synaptic autoimmunity as a cause of teratoma-associated encephalitis, epilepsy and herpetic post-encephalic recidivism in childhood", directed by Dr. Josep Dalmau, from the Department of Medicine of the Faculty of Medicine and Health Sciences

  • I survived autoimmune encephalitis. Mauren Rivera Serrano, Costa Rica.

    My name is Mauren Rivera Serrano, I am 21 years old and I am a student in Industrial Design Engineering at the Universidad del Tecnológico de Costa Rica. I suffered from Autoimmune Encephalitis due to the Neurexin 3- Alpha antibody and now I am completely recovered.

    Published at Patients section

  • World Encephalitis Day - WED2018

    World Encephalitis Day on February 22 is the global awareness day for people who have been affected by encephalitis (inflammation of the brain). It was founded by The Encephalitis Society in 2014 and has subsequently helped to raise awareness among millions of people.

    Eight out of 10 people across the world do not know what encephalitis is. That is a startling figure which we are determined to change if we are to achieve our vision of a world which is aware of encephalitis, its consequences and the support available.

    The Encephalitis Society is the only resource of its kind in the world providing direct support and information to individuals and families affected by encephalitis.